News & Updates

Baricitinib, ivermectin, and favipiravir stood out in terms of efficacy in a network meta-analysis evaluating various novel oral antivirals for the treatment of COVID-19.

In the second interim analysis of the Asian cohort from the phase III MAGNITUDE study, a combination regimen comprising niraparib and abiraterone acetate plus prednisone (NIRA-AAP) improved clinical outcomes in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC).

In the treatment of patients with rifampicin-resistant tuberculosis, a 6-month oral regimen consisting of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) is safe and efficacious and compares favourably with standard of care, as shown in the final data from the phase IIB-III TB-PRACTECAL study.

A recent study has demonstrated the feasibility of molecular-based targeted therapy in patients with hepatocellular carcinoma (HCC)/hepato-cholangiocarcinoma (H-CCK) that progressed while under treatment with atezolizumab/bevacizumab.

Both mepolizumab and benralizumab are effective in improving the clinical outcomes of patients with severe eosinophilic asthma, as shown in a recent study. However, treatment with benralizumab appears to be better than mepolizumab in reducing exacerbations, improving forced expiratory volume, and depleting blood eosinophils.

In the treatment of patients with acute ischaemic stroke, treatment with exenatide does not appear to have any beneficial effect on neurological function at 7 days but is safe and substantially decreases the frequency of hyperglycaemic events, without leading to hypoglycaemia, according to the results of the phase II TEXAIS trial.